(2)
WESTON (dpa-AFX) - Today s Daily Dose brings you news about Biogen pulling the plug on a potential Parkinson s drug, Jazz Pharma acquiring GW Pharmaceuticals, Neurocrine terminating its agreement with Voyager related to Parkinson s disease drug development, and Vaxart s phase I study results of oral COVID-19 tablet vaccine candidate.
Read on.
1. Biogen throws in the towel on potential Parkinson s Drug
Biogen Inc. (BIIB) has discontinued the development of BIIB054 (Cinpanemab), a potential Parkinson s drug, following the failure of that compound in a phase II study.
The phase II study of BIIB054, dubbed SPARK, has not met its primary or secondary endpoints. The company has recognized an impairment charge of approximately $75.4 million during the fourth quarter of 2020, as a result of terminating BIIB054.